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Abstract
Feline immunodeficiency virus (FIV) infection in cats follows a disease course similar to HIV-1, including a short acute phase
characterized by high viremia, and a prolonged asymptomatic phase characterized by low viremia and generalized immune
dysfunction. CD4
+CD25
hiFoxP3
+ immunosuppressive regulatory T (Treg) cells have been implicated as a possible cause of
immune dysfunction during FIV and HIV-1 infection, as they are capable of modulating virus-specific and inflammatory
immune responses. Additionally, the immunosuppressive capacity of feline Treg cells has been shown to be increased
during FIV infection. We have previously shown that transient in vivo Treg cell depletion during asymptomatic FIV infection
reveals FIV-specific immune responses suppressed by Treg cells. In this study, we sought to determine the immunological
influence of Treg cells during acute FIV infection. We asked whether Treg cell depletion prior to infection with the highly
pathogenic molecular clone FIV-C36 in cats could alter FIV pathogenesis. We report here that partial Treg cell depletion
prior to FIV infection does not significantly change provirus, viremia, or CD4
+ T cell levels in blood and lymphoid tissues
during the acute phase of disease. The effects of anti-CD25 mAb treatment are truncated in cats acutely infected with FIV-
C36 as compared to chronically infected cats or FIV-naı ¨ve cats, as Treg cell levels were heightened in all treatment groups
included in the study within two weeks post-FIV infection. Our findings suggest that the influence of Treg cell suppression
during FIV pathogenesis is most prominent after Treg cells are activated in the environment of established FIV infection.
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Introduction
The acute phase of infection with HIV-1, simian immunode-
ficiency virus (SIV), and feline immunodeficiency virus (FIV) is
characterized by robust viral replication that is usually controlled,
but not eliminated, by innate, cell-mediated, and humoral antiviral
immune responses [1,2,3,4]. During this acute phase, Treg cells
have been variably reported to increase, decrease or not change
depending on the virus/host system and tissues evaluated. An
important question is whether Treg cells, present or induced at the
time of infection, suppress a robust anti-viral immune response.
This question is complicated by data that show Treg cells are
susceptible to lentiviral infection and are depleted along with
conventional CD4
+ T cells during acute lentiviral infection [5,6,7].
The clinically relevant issue is whether depletion of Treg cells
during the acute phase of HIV-1 infection might alter the viral
and/or immunological set-points thereby improving clinical
outcome.
In vivo depletion of Treg cells is complicated by the fact that no
Treg specific cell surface marker has been identified. The IL-2
receptor alpha chain, CD25, remains the best target although
CD25 is neither universally expressed on cells with regulatory
function nor is it specific since many activated cell types are known
to express CD25. Nevertheless, in vivo depletion of CD25
+ Treg
cells is under intense investigation as a primary or adjunctive
immunotherapy against various types of cancer [8]. If Treg cell
depletion was to be attempted in acutely HIV-1 infected people,
drugs that target CD25 would be the logical choice.
Feline immunodeficiency virus is a natural lentiviral pathogen of
outbred domestic and wild cats that causes an immunodeficiency
syndrome very similar to HIV/AIDS. It has previously been
shown that feline Treg cells are activated and more suppressive
during the acute and chronic phases of FIV infection [9,10].
Similarly, HIV-1 can enhance human Treg cell suppressive
capacity [11,12]. Multiple studies have quite clearly shown that
Treg cells from hosts infected with HIV-1, SIV or FIV suppress
antiviral responses during the chronic phase of disease [5,13,14,
15,16,17]. We have previously shown that transient in vivo Treg
cell depletion during chronic FIV infection unmasks FIV-specific
immune responses [18]. Only a few studies have addressed this
issue in the acute phase. A correlation between Treg cell induction
and limited anti-SIV immune responses during acute infection has
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17183been demonstrated [19] and individuals with more robust anti-
lentiviral responses possess lower Treg cell frequencies [5,7,20].
These data suggest that Treg cell suppression of antiviral
immunity may occur at the earliest stages of the immune response.
In this study we sought to determine whether Treg cell
depletion using an anti-feline CD25 monoclonal antibody prior
to natural lentiviral infection in the well-characterized FIV/cat
model would alter the immunologic or virologic set-point. We
hypothesized that this could occur either due to removal of Treg
cell immunosuppression leading to heightened antiviral responses
and/or due to removal of Treg cells that host lentiviral infection
and replication. We report here that Treg cell depletion prior to
FIV infection does not significantly change viral load or CD4
+ T
cell levels in tissues. The effects of anti-CD25 mAb treatment are
truncated in cats acutely infected with FIV as compared to
chronically infected cats or FIV naı ¨ve cats, as Treg cell levels were
heightened in all treatment groups within two weeks following FIV
infection. We propose that the influence of Treg cell suppression
during FIV infection is most prominent after established infection,
when Treg cells are activated and more functionally suppressive.
Materials and Methods
Ethics Statement
All experimental manipulations and protocols (08-019-B) were
approved by the North Carolina State University Institutional
Animal Care and Use Committee. The animals were housed and
maintained in accordance with standards established in the
Animal Welfare Act and the Guide for the Care and Use of
Laboratory Animals.
Animals, Viral Inoculum, and Monoclonal Antibody
Administration
A total of 24 female specific-pathogen-free (SPF) cats were
purchased from Liberty Labs (Liberty, NY). Mouse anti-feline
CD25 hybridoma (9F23) [21], a generous gift from M. Honda of
the National Institutes of Health in Tokyo, Japan, and mouse anti-
yellow fever antigen (YFA) hybridoma (CRL-1689; ATCC,
Figure 1. Anti-CD25 monoclonal antibody treatment depletes
Treg cells in cats. Cats received 9 mg/kg anti-CD25 mAb (9F23) (n=8)
or 9 mg/kg isotype control mAb (CRL-1689) (n=8) i.p. on day 212. A
third group of cats received 3 mL/kg saline on day 212 (n=8). (A)
PBMCs were labeled with antibodies for CD4 and CD25 and analyzed by
flow cytometry for CD4
+CD25
hi percentages within the lymphocyte
population on days 212, 0, 7, 14, 35, and 54 post-FIV infection.
Percentages were multiplied by lymphocyte absolute number to
quantify absolute numbers of CD4
+CD25
hi cells. (B) CD4
+CD25
+FoxP3
+
cell percentages were determined by flow cytometry.
CD4
+CD25
+FoxP3
+ absolute number was calculated. Mean 6 SEM is
shown. * indicates p,0.05.
doi:10.1371/journal.pone.0017183.g001
Figure 2. Anti-CD25 mAb treatment does not significantly alter
FIV levels in the blood. Cats were infected with 2610
5.2 TCID50 units
molecular clone FIV-C36 by intravaginal and intravenous routes on day
0. (A) To detect viremia in plasma samples, one-step quantitative real-
time RT-PCR was performed on extracted RNA samples. FIV RNA copy
number was quantified relative to an FIV C gag RNA standard curve. (B)
Provirus in PBMCs was detected via quantitative real-time RT-PCR on
extracted DNA samples. FIV copy number was quantified relative to an
FIV C gag DNA standard curve, and then normalized relative to CCR5
copy number. Mean 6 SEM is shown (n=8/group).
doi:10.1371/journal.pone.0017183.g002
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purified and certified endotoxin- and mycoplasma-free by Leinco,
Inc. (St. Louis, MO). One group of cats received a single injection of
9 mg/kg anti-feline CD25 mAb intraperitoneally (i.p.) between 25
and 31 weeks of age and 12 days prior to infection with FIV-C36
[22]. Another group was treated with 9 mg/kg anti-YFA mAb i.p.
as a mouse IgG2a k light chain isotype control mAb and a third
group was treated with 3 mL/kg 0.9% sodium chloride (Hospira,
Lake Forest, IL) i.p. as a vehicle control. All cats were infected with
1610
5.2 TCID50 units molecular clone FIV-C36 [23] intravaginally
along with 1610
5.2 TCID50 units FIV-C36 intravenously 12 days
after mAb or saline treatment. Titered FIV-C36 was a generous gift
from Dr. Sue VandeWoude of Colorado State University.
Sample Collection and Processing
Whole blood was collected into Vacutainer tubes (BD, Franklin
Lakes, NJ) containing ACD on days 212, 0, 7, 14, 35, and 54 post-
infection (p.i.). Peripheral blood mononuclear cells (PBMCs) were
isolated by centrifugation of blood over Histopaque (Sigma, St. Louis,
MO) and serum was processed as previously described [24,25]. Blood
for plasma isolation, complete blood counts, and leukocyte
differentials was collected in Vacutainer tubes containing EDTA.
Plasma was isolated by centrifugation (11006g for 10 min) and
aliquots were frozen at 280uC for subsequent RNA isolation.
Popliteal lymph node (LN) biopsies were performed on anesthetized
cats on days 14 and 35 p.i. At day 54 p.i., mesenteric and
retropharyngeal LNs in addition to spleen were harvested and
processed as described previously [26]. Cells were used immediately
in ex vivo assays or cell aliquots were frozen at 280uC for subsequent
DNA isolation.
Phenotypic Analysis
At least 1610
6 cells were labeled with the following antibodies
for flow cytometric analysis. Antibodies against feline CD3
(NZM1) [27], CD4 (30A) [28], CD8a (3.357) [28], and IFN-c
(E6D4A5) [29] were purified from hybridoma supernatants in our
lab. Anti-CD80 (B7.1.66) was generously provided by Dr. Mary
Tompkins of North Carolina State University [30]. Anti-CD1a
(Fe1.5F4) was provided by Dr. Peter Moore of the University of
California at Davis [31]. Antibodies against CD56 and IL-2 were
purchased from BioLegend (San Diego, CA). Antibodies against
Ki67 and TNF-a were purchased from BD Biosciences (San
Diego, CA). Anti-B220 was purchased from Southern Biotech
(Birmingham, AL). Anti-TGF-b was purchased from R&D
Systems (Minneapolis, MN). Anti-MHC II was purchased from
Serotec (Raleigh, NC). Some antibodies were conjugated to Pacific
Blue, Pacific Orange, Alexa Fluor 647, or biotin using kits from
Invitrogen Molecular Probes (Carlsbad, CA). Some antibodies
were conjugated to PerCP or PE using kits from Prozyme (San
Leandro, CA). Mouse anti-feline CD25 (9F23) was conjugated to
FITC using standard protocols. Anti-mouse IgG3-APC (Jackson
ImmunoResearch, West Grove, PA), anti-mouse IgG3-APC-Cy7
Figure 3. FIV proviral load in tissues is unaffected by anti-CD25 mAb treatment. (A–B) Provirus in popliteal lymph nodes was quantified on
days 14 and 35 p.i. (C–E) Provirus in mesenteric and retropharyngeal lymph nodes and spleen was quantified on day 54 p.i. * indicates p,0.05.
doi:10.1371/journal.pone.0017183.g003
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were used for secondary detection. Intracellular FoxP3 staining
was performed with eBioscience FoxP3 staining buffers and
FoxP3-PE-Cy7 (FJK-16s; San Diego, CA) according to manufac-
turer’s protocol, with the exception that cells remain in the
permeabilization/wash buffer no longer than 30 min. For
intracellular cytokine staining, cells were incubated with 16
monensin (BioLegend, San Diego, CA) for six hr, labeled for
surface markers, fixed with 4% paraformaldehyde, permeabilized
with BD Cytofix/Cytoperm kit Perm/Wash buffer, and stained
with anti-cytokine mAbs. For intracellular Ki67 staining, cells were
first labeled for surface markers, incubated with BD Cytofix/
Cytoperm for 15 min, washed with BD Perm/Wash buffer,
incubated with BD Cytoperm Plus for 10 min, washed, and
incubated with BD Cytofix/Cytoperm for 5 min. Cells were then
labeled with anti-Ki67. Flow cytometric analysis was performed
using an LSR II flow cytometer and FacsDIVA software (BD).
100,000–1,000,000 gated events were collected per sample.
Viral Parameters
Quantitative real-time one-step reverse transcriptase (RT)-PCR
assays to quantify viremia were performed on a Bio-Rad MyiQ
TM
PCR detection system (Hercules, CA). RNA was extracted from
plasma using the QIAamp viral RNA mini kit (QIAGEN,
Valencia, CA) following manufacturer’s protocol. Detection of
plasma viremia in RNA samples was performed using FIV-C gag
specific primers 704f and 756r and probe 727p [32]. Each RNA
sample was combined with TaqMan RT-PCR Mix (Applied
Biosystems, Branchburg, NJ), TaqMan RT Enzyme Mix (Applied
Biosystems), 400 nM forward and reverse primers, and 80 nM
TaqMan probe. Plasma viremia RT-PCR cycling conditions were
as follows: 30 min at 48uC, 10 min at 95uC, and 50 cycles of a
15 sec step at 95uC followed by a 1 min step at 55.5uC.
Fluorescence was recorded at the end of each annealing/extension
step. RNA standards were generated by in vitro transcription of a
pGEM-T Easy plasmid (Promega, Madison, WI) encoding FIV
clade C gag using the T7 MAXIscript kit (Applied Biosystems)
according to manufacturer’s instructions. A 10-fold dilution series
of RNA standards provided a detection range from 10
1 to 10
5
RNA molecules per reaction. Bio-Rad MyiQ
TM optical system
software v2.0 was used to generate a standard curve; viral RNA
copies/mL plasma was subsequently calculated.
To detect proviral load in PBMC and tissue samples, quantitative
PCR was performed on DNA samples extracted with the DNeasy
blood and tissue kit (QIAGEN).Each amplification reaction included
0.5 mg DNA sample, TaqMan universal PCR master mix (Applied
Biosystems), 400 nM 704f and 756r primers,and 40 nM 727p probe.
Real-time PCR cycling conditions were as follows: 2 min at 50uC,
10 min at 95uC ,a n d4 5c y c l e so fa1 5ss t e pa t9 5 uC followed by a
1 min step at 55.5uC. To normalize proviral load per 10
6 cells, a 10-
fold dilution series of a pGEM-T Easy plasmid encoding FIV C gag
was used to provide a detection range of 10
1 to 10
5 copies. A
quantitative PCR was performed to detect CCR5 copies in 0.5 mg
DNA sample as previously described [18]. The limit of detection was
#10 copies of FIV per 1 mg DNA. Standards, controls, and samples
were run in duplicate for real-time PCRs.
Peptides
The entire FIV p24 protein sequence was synthesized by JPT
(Springfield, VA) consisting of 40 15-aa peptides overlapping by 10
Figure 4. Peripheral lymphocyte dynamics during acute FIV-C36 infection are not altered by anti-CD25 mAb treatment. Absolute
numbers of (A) CD3
+CD4
+, (B) CD3
+CD8
+, (C) CD3
2B220
+ (B cells), and (D) CD3
2CD56
+ (NK cells) lymphocytes in the periphery were quantified on
days 212, 0, 7, 14, 35, and 54 p.i. based on percentages obtained by flow cytometry and absolute number of peripheral lymphocytes. Mean 6 SEM is
shown (n=8/group).
doi:10.1371/journal.pone.0017183.g004
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dimethyl sulfoxide (DMSO), or 100% DMSO according to
solubility and stored at 280uC.
Interferon-c ELISpot
Capture and detection antibodies from the feline IFN-c
detection module (R&D Systems) were used with ELISpot
Immobilon-P 96-well plates (Millipore, Bedford, MA) to quantify
IFN-c-producing cells after stimulation with FIV p24 peptides as
previously described [33]. The protocol was modified to use of 2.5
or 5610
5 fresh instead of frozen cells/well.
IgG Titers Determined by ELISA
Serum IgG titers against mouse antibody were determined by
ELISA as previously described [22]. For the FIV p24 antibody
ELISA, Immulon-2HB plates (Nalge Nunc International, Roch-
ester, NY) were coated with 1.0 mg/mL p24-GST fusion protein
and the assay was performed as previously described [34]. For the
FIV gp95 antibody ELISA, Lumitrac 600 high-binding plates
(Greiner Bio-One, Monroe, NC) were coated with 2.5 mg/mL
gp95-Fc antigen [35] diluted in carbonate buffer (15 mM
Na2CO3, 35 mM NaHCO3, pH 9.5). Plates were blocked with
200 mL/well blocking buffer (3% nonfat dry milk, 5% goat serum,
0.1% Kathon in carbonate buffer) for 2 hr at room temperature.
Plates were washed four times with wash buffer (0.5% Tween 20 in
16PBS). Serum samples were diluted in complete sample diluent
(2.5% human serum, 1% bovine serum albumin, 1% nonfat dry
milk, 0.05% Tween 20, 0.1% Kathon in 16 PBS) and added to
blocked plates at 100 mL/well. Plates were incubated for three hr
at 37uC and then washed four times with wash buffer. Antibody
was identified with goat anti-cat IgG-horseradish peroxidase
(HRP) (Bethyl Labs, Montgomery, TX) diluted 1:80,000 in
complete sample diluent and incubated for one hr at room
temperature. Plates were washed five times. 100 mL/well Pierce
SuperSignal ELISA Femto chemiluminescent substrate (Rockford,
IL) was added to plates. Plates were read on a Perkin Elmer
Wallac Victor
3 1420 Multilabel Counter (Waltham, MA) 2 min
after addition of substrate. A threefold higher optical density of
tested sample over pre-infection samples determined positive
antibody titers.
Statistics
Comparisons between post-treatment or post-infection data to
baseline values within groups were made using unpaired t-tests.
Comparisons between treatment groups were made using 1-way
ANOVA with Tukey’s post-test. Statistics were calculated using
GraphPad Prism version 5.0 (GraphPad Software, San Diego,
CA).
Results
Anti-CD25 monoclonal antibody treatment depletes Treg
cells in cats prior to FIV infection
Twenty-four SPF cats were divided into three groups of eight
cats each, with siblings distributed across the groups. Cats received
anti-CD25 mAb, isotype control mAb, or saline by i.p. route on
day 212 relative to the date of infection with FIV-C36. FIV-C36
is a highly pathogenic molecular clone of an FIV clade C isolate
[23]. Acute FIV-C36 infection is characterized by very high peak
viremia and substantial CD4
+ T cell loss, leading to early
symptoms of immunodeficiency [23,36]. Cats received 2610
5.2
TCID50 units FIV-C36 on day 0, at the previously determined
nadir of CD4
+CD25
hi cell depletion following treatment with anti-
CD25 mAb [18,22]. Expression of CD25 and FoxP3 were used to
identify Treg cells. Treg cells express CD25 more densely than
conventional T cells, and the transcription factor FoxP3 is
associated with Treg cell function. Anti-CD25 mAb administra-
tion resulted in a 78% average reduction in circulating
CD4
+CD25
hi T cells (Figure 1A) and a 50% average reduction
in CD4
+CD25
+FoxP3
+ T cells by day 0 (Figure 1B).
CD25 depletion does not significantly alter viral load
during acute FIV infection
It has been hypothesized that Treg cells are either more
frequently infected by latent lentivirus [9,37] or are more efficient
virion producers when infected as compared to conventional T
cells [38,39,40,41]. Treg cell depletion using the IL-2–toxin fusion
protein denileukin diftitox prior to HIV-1 infection in humanized
mice has been shown to reduce plasma viremia on days 4–10 p.i.
[37]. It is therefore possible that reduced Treg cell levels at the
onset of lentiviral infection could result in reduced viremia or
provirus levels during acute infection. It is also possible that Treg
Figure 5. T cell proliferation due to FIV infection is not
enhanced by anti-CD25 mAb treatment. Percent (A) CD4
+ Ki67
+
T cells and (B) CD8
+ Ki67
+ T cells in circulation were quantified by flow
cytometry on days 212, 0, 7, 14, 35, and 54 p.i. (n=8/group). Mean 6
SEM is shown. Significance is relative to day 0 values for each group. No
significant differences were found between treatment groups.
* indicates p,0.05.
doi:10.1371/journal.pone.0017183.g005
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responses, or that Treg cell depletion could increase viral load due
to elevated immune activation and viral replication.
We found that Treg cell depletion at the onset of FIV infection
does not cause significant changes in viremia or proviral load. A
trend of higher viremia and peripheral blood mononuclear cell
(PBMC) proviral load was found in the CD25 depleted group as
compared to the control groups on days 14 and 35 p.i. (Figure 2A
and 2B). Proviral load was evaluated at intermediate time points in
popliteal lymph nodes sampled on days 14 and 35 p.i.; however,
no differences were observed among treatment groups (Figure 3A
and 3B). In tissues evaluated terminally at day 54 p.i., proviral
load was significantly higher in the mesenteric lymph nodes of
CD25 depleted cats as compared to vehicle control cats, but not
isotype control cats (Figure 3C). Similarly, proviral load in the
retropharyngeal lymph nodes of CD25 depleted cats tended to be
higher than in retropharyngeal lymph nodes of control cats
(Figure 3D). However, no differences were observed in the spleen
(Figure 3E). Both viremia and proviral levels reached set-point by
day 54 p.i. in all cats (Figure 2 and 3). Our data indicate that anti-
CD25 mAb treatment prior to FIV-C36 infection does not reduce
and may in fact slightly augment viral load during acute infection.
Lymphocyte dynamics and immune cell activation
during acute FIV infection are not altered by anti-CD25
mAb treatment
Depletion of CD25
+ Treg cells using anti-CD25 mAbs in acute
infection models has raised concerns that there may be concomitant
depletion of activated effector cells [42]. To avoid this, it was
important to administer anti-CD25 mAb in a timeframe that
allowed the majority of anti-CD25 mAb to bind to Treg cells or be
cleared before effector cells were generated. We infected cats with
FIV-C36 12 days after administration of anti-CD25 mAb, which
allowed depletion of the majority of Treg cells before infection.
Acute pathogenic FIV infection is characterized by a dramatic
decline in peripheral CD4
+ T cell counts with a slight decline in
CD8
+ T cells developing around or directly following the
occurrence of peak viremia [32]. CD4
+ T cell counts rebound to
a degreebutremainlowerthanpre-infectionlevelsastheygradually
decline throughout the course of the disease. Cytotoxic CD8
+ T
cells eventually expand to higher than baseline levels as they
respond to infection [32,43]. We observed characteristic CD4
+ and
CD8
+ T cell dynamics during acute FIV-C36 infection (Figure 4A
and 4B). In the control group cats, B cells were decreased on day
14 p.i., but cats in the CD25 depleted group did not experience a
similar transient B cell decline (Figure 4C). Natural killer (NK) cells
were decreased in all three groups on day 14 p.i., and an increase in
NK cell absolute numbers was observed on day 35 p.i. (Figure 4D).
No significant differences were observed in T cell, B cell, or NK cell
dynamics between treatment groups in PBMC (Figure 4) or in
lymphoid tissues (data not shown). There were also no differences in
CD4:CD8 T cell ratios in tissues, nor differences in cell density and
cellularity in the lymph nodes between the groups (data not shown).
Treg cells have been shown to suppress lentiviral-specific T cell
proliferation ex vivo [16,44]. We asked whether Treg cell
depletion in vivo could augment T cell proliferation after FIV
infection. T cell proliferation in the periphery was determined via
Ki67 expression. CD4
+ T cell proliferation was significantly
increased in control groups on day 14 p.i., corresponding with the
CD4
+ T cell nadir and peak viremia (Figure 5A). CD8
+ T cell
proliferation was significantly increased at days 14, 35, and 54 and
was maximal at day 35 p.i. in all three treatment groups
(Figure 5B). Peripheral Ki67
+ B cell and Ki67
+ NK cell
frequencies did not change significantly after FIV infection and
were not significantly different between the groups (data not
shown). Ki67 expression by lymphocyte subsets in tissues was not
significantly different between the groups on days 14, 35, or 54 p.i.
(data not shown).
Figure 6. Cytokine-expressing CD8
+ T cell levels are lower after anti-CD25 mAb treatment on day 35 post-FIV infection. Popliteal
lymph node cells were incubated with monensin for 6 hours prior to quantification of cytokine expressing cells. Percent TNF-a-, IL-2-, and IFN-c-
expressing cells in CD4
+ and CD8
+ T cell populations were quantified by flow cytometry (n=8/group). Mean 6 SEM is shown. * indicates p,0.05.
doi:10.1371/journal.pone.0017183.g006
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+ T cell levels are lower after
anti-CD25 mAb treatment on day 35 post-FIV infection
Intracellular expression of cytokines TNF-a, IL-2, and IFN-c
was determined in popliteal lymph node CD4
+ and CD8
+ T cells
during acute FIV infection in controland CD25 depleted cats. No
significant differences in cytokine expression by T cells were found
between the treatment groups at day 14 p.i. (Figure 6). In contrast,
CD8
+TNF-a
+ cell levels were significantly lower in the CD25
depleted group as compared to the vehicle control group at day
35 p.i., and there was a trend of lower IL-2 and IFN-c expression
by CD8
+ T cells in the CD25 depleted group as well. Cytokine
expression by CD4
+ T cells at day 35 p.i. was not significantly
different between the groups (Figure 6). By day 54 p.i. no
differences were observed in T cell cytokine expression between
treatment groups in mesenteric lymph node, retropharyngeal
lymph node, and spleen (data not shown).
Cellular and humoral anti-FIV specific responses are
slightly depressed in anti-CD25 mAb treated cats
We have previously shown that in vivo Treg cell depletion in
cats chronically infected with FIV unmasks existing FIV-specific
IFN-c secreting cells [18]. We asked whether CD25 depletion
before FIV infection would allow a more robust induction of FIV-
specific immune responses. Lymphocytes were stimulated with
FIV p24 peptides in an IFN-c ELISpot assay. No significant
differences were found between the groups; however, there was a
trend of fewer FIV-specific IFN-c secreting cells in the CD25
depleted group as compared to the control groups in tissues
analyzed from days 14, 35, and 54 p.i. (Figure 7).
Neutralizing antibodies have been shown to play a role in
controlling FIV replication. Anti-FIV gp95 IgG titers were not
significantly different between the groups during acute FIV
infection (Figure 8A); however, anti-FIV p24 IgG titers were
significantly higher in the vehicle control group as compared to the
CD25 depleted group on days 7 and 14 p.i. (Figure 8B). These
data may explain why viral load was slightly higher in the CD25
depleted group at certain time points during acute infection.
Kinetics and characterization of Treg cell induction
during acute FIV infection
Throughout the study, we tracked Treg cell levels and
properties. We found that peripheral Treg cell frequency increases
substantially during acute FIV infection. Peripheral CD4
+CD25
hi
cells were slightly reduced at day 14 p.i. in the isotype control and
Figure 7. FIV-specific IFN-c responses during acute infection are not altered by anti-CD25 mAb treatment. Popliteal lymph node cells
from day 14 and 35 p.i. and mesenteric and retropharyngeal lymph node cells and spleen cells from day 54 p.i. were incubated for 48 hours with
100 mg/mL FIV p24 peptides or 1% DMSO/media as a background control. IFN-c spot forming cells (SFCs) per million cells from CD25 depleted,
isotype control, and vehicle control treated groups in response to FIV p24 minus background were determined by ELISpot (n=8/group).
doi:10.1371/journal.pone.0017183.g007
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peak viremia and depletion of total CD4
+ T cells as a result of
pathogenic FIV infection (Figure 2 and 4A). In all groups
CD4
+CD25
hi cells exceeded baseline levels by day 35 p.i.
(Figure 9A). In the anti-CD25 mAb treated group, peripheral
CD4
+CD25
+FoxP3
+ cells exceeded baseline levels by day 14 p.i.
(Figure 9B).
CD4
+CD25
+FoxP3
+ cells rebounded more quickly and to a
higher degree after CD25 depletion in acutely infected cats as
compared to FIV naı ¨ve or chronically infected FIV
+ cats
(Figure 1B) [18,22]. Control group cats also exhibited increased
absolute numbers of CD4
+CD25
+FoxP3
+ cells by day 14 p.i.
(Figure 9B). This effect is presumably due to Treg cell conversion
and/or proliferation in response to FIV infection. We found that
FoxP3 protein expression increased in CD4
+CD25
2FoxP3
+ cells
by day 7 p.i., and this was followed by a decrease in FoxP3
expression by CD4
+CD25
2 cells and an increase in FoxP3
expression by CD4
+CD25
+cells at day 14 p.i. (Figure 9C). This
suggests that CD4
+CD25
2FoxP3
+ cells were converting to
CD4
+CD25
+FoxP3
+ cells between days 7 and 14 p.i. In addition,
TGF-b protein expression increased in CD4
+CD25
+ cells at the
same time FoxP3 protein expression increased (Figure 9D). TGF-b
has been associated with one mechanism of Treg cell suppression
in cats [45]. CD62L
+ cell frequency also increased within the
CD4
+CD25
+FoxP3
+ cell population throughout the study
(Figure 9E). The early activation marker CD62L has been shown
to distinguish Treg cells from T effector cells in mice [46].
CD4
+Ki67
+ cell kinetics in the periphery mirror the increase in
absolute number of CD4
+CD25
+FoxP3
+ cells (Figure 9F). This
suggests that Treg cell proliferation may contribute to the increase
in peripheral Treg cell absolute number during acute FIV
infection. These data indicate increased peripheral Treg cell
presence in all cats during acute FIV-C36 infection regardless of
treatment.
CD4
+CD25
+FoxP3
+ cell levels were not reduced in popliteal
lymph nodes at day 14 or day 35 p.i. in the CD25 depleted group
as compared to the control groups (Figure 9G). We were not able
to determine changes in Treg cell levels in tissues after FIV
infection, as lymph nodes were not biopsied prior to infection.
Discussion
Regulatory T cells have been shown to suppress function of
CD4
+ and CD8
+ effector T cells, natural killer cells, and dendritic
cells. During chronic FIV, SIV or HIV-1 infection it is clear that
Treg cells suppress antiviral responses in vitro [10,12,13,14]. We
have shown that this suppression is also exerted in vivo during
chronic FIV infection [18]. Whether the net effect of suppressing
chronic immune activation is beneficial likely depends on the
immunologic and virologic set-point of any given individual. The
present study sought to determine whether Treg cell depletion at
the time of FIV infection might allow a more robust anti-viral
immune response that would result in an improved immunologic
set-point and a decreased virologic set-point. Our results show this
is not the case. Treatment with anti-CD25 antibody effectively
depleted Treg cells as measured by the frequency of CD4
+CD25
hi
cells or CD4
+CD25
+FoxP3
+ cells (Figure 1). Nevertheless, antigen
specific CD8
+ T cell responses were not improved over control
animals and neither were antiviral antibody titers. Similarly, viral
burden, whether measured as plasma viremia or proviral copy
number in blood or tissues, was the same or greater in Treg cell
depleted cats. Thus we conclude that Treg cells present at the time
of infection do not alter the immune response against FIV. In
addition, our data indicate that Treg cells present at the time of
FIV infection are not major reservoirs of virus during the first few
days after infection.
Depletion of Treg cells at the time of antigenic stimulation has
resulted in variable outcomes. Several studies have shown that
Treg cell depletion immediately prior to or at the time of
vaccination results in increased antigen-specific responses to the
vaccine [47,48,49,50]. Results from similar studies involving Treg
cell depletion at the time of challenge with an infectious agent have
been variable. For example, Treg cell depletion did not improve
the immune response in mice challenged with Plasmodium yoelii,
Trypanosoma cruzi or Psuedomonas aruginosa [51,52,53]. Even though
Treg cell depleted mice challenged with rotavirus had improved
antigen-specific CD4
+ and CD8
+ T cell responses, the clinical
outcome was not improved [54]. The difference between immune
induction with vaccines versus infectious agents under conditions
of Treg cell depletion may be related to the strength of activation
signals to effector versus regulatory T cells. It has been shown that
production of certain cytokines or ligation of certain toll-like
Figure 8. Anti-FIV p24, but not anti-FIV gp95, IgG titers are
significantly lower after anti-CD25 mAb treatment during
acute FIV infection. (A) Anti-FIV gp95 and (B) anti-FIV p24 IgG titers
were quantified in serum samples on days 0, 7, 14, 35, and 54 post-FIV
infection. Positive antibody titers were calculated based on a 3-fold
higher optical density than day 0 pre-inoculation controls. Mean 6 SEM
is shown. Statistical significance was determined between treatment
groups for each time point (n=8/group). * indicates p,0.05.
doi:10.1371/journal.pone.0017183.g008
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refractory to Treg cell suppression or temporarily disrupt Treg cell
suppressive function [55]. It seems likely that infectious agents
provide a greater quantity of antigen, DC activation, and IL-2
production as compared to the limited antigen available by
vaccination. This would result in T effectors that are more likely to
be refractory to Treg cell suppression in the infection scenario.
The importance of the strength of T-cell receptor signals has been
clearly demonstrated for HIV-specific responses by Antons et al.
[56]. FIV-C36 acute infection causes massive immune activation,
and we did not observe changes in effector cell activation after
Treg cell depletion and infection. It is likely that during acute FIV
infection effector cells are resistant to any concurrent immuno-
suppressive effects mediated by Treg cells.
One important caveat regarding the present study and those
mentioned previously is that anti-CD25 mAb was used for Treg cell
depletion. This approach is limited in its specificity and efficacy.
CD25 is expressed by many cell types, including recently activated
T effector cells, thereby limiting the utility of anti-CD25 treatment
to the time frame prior to effector T cell activation. Furthermore,
not all CD25
+ Treg cells are depleted by the mAb nor do all Treg
cellsexpressCD25.Thedevelopmentofmicethat aretransgenicfor
co-expression of FoxP3 and diphtheria toxin receptor allows
selective depletion of nearly all FoxP3 expressing cells [57].
Zelinskyy et al. exploited this system in conjunction with Friend
retrovirus infection and showed continuous FoxP3
+ cell depletion
resulted in increased CD8
+ T cell responses and lower viral burden
[58]. These results suggest the acute antiviral response might be
improved by Treg cell depletion butthe depletion mustbe sustained
during the time when Treg cells are simultaneously induced with T
effector cells. Obviously such an approach is not possible in humans
or outbred models such as the cat, nor is FoxP3 exclusively
expressed in Treg cells of either of these species [59,60].
Investigation of clinically feasible Treg cell manipulation for human
patients is limited to the currently available strategies that target
CD25, including the IL-2–toxin fusion protein denileukin diftitox
and anti-CD25 mAbs. Treg cell depletion may be more effective in
the presence of low antigen levels as is the case with most vaccines.
Under conditions of low antigen the balance between effector
responses versus Treg cell suppression is more likely to be tipped
toward Treg cell suppression. This could mean that Treg cell
depletion before vaccination would boost immunity. In support of
this hypothesis, it has been shown that HIV-1-specific Treg cells
induced after therapeutic DC vaccination in HIV-1-infected
patients significantly inhibit development of polyfunctional CD8
+
T cell responses [61]. It remains to be determined whether Treg cell
depletionpriortotherapeuticHIV-1vaccinationwouldbesufficient
to reduce immunosuppression in a clinically significant manner.
Despite Treg cell depletion prior to FIV infection, the kinetics of
Treg cell induction associated with FIV were not altered. The
absolute number of CD4
+CD25
+FoxP3
+ cells was increased at day
14 p.i. and remained elevated through day 35 p.i., reaching a
plateau or declining by day 54 p.i. We hypothesize that elevation
in peripheral CD4
+CD25
+FoxP3
+ cell numbers was due to new
expression of CD25 by cells that were CD4
+CD25
2FoxP3
+ at the
time of FIV infection. Our data show that FoxP3 protein
expression increased in CD4
+CD25
2FoxP3
+ cells by day 7 p.i.,
and this was followed by a decrease in FoxP3 expression by
CD4
+CD25
2 cells and an increase in FoxP3 expression by
CD4
+CD25
+cells at day 14 p.i. (Figure 9C). This suggests that
FoxP3 upregulation was followed by CD25 expression and a
transition of cells to the phenotype CD4
+CD25
+ known to harbor
activated, suppressive Treg cells in the cat [22]. This idea is
supported by adoptive transfer studies in the mouse showing that
de novo Treg cell generation during acute malaria infection was
not due to proliferation of CD25
+FoxP3
+ cells or differentiation of
CD25
2FoxP3
2 cells but rather was the result of proliferation of
CD25
2FoxP3
+ cells that simultaneously began expressing CD25
[62]. These studies demonstrated suppressive function in the
CD4
+CD25
2FoxP3
+ population although the lack of CD25
expression might be an artifact of in vivo treatment with the
anti-CD25 mAb 7D4, that is reported to induce shedding of CD25
[62]. It is not possible to functionally assess the CD25
2FoxP3
+
population in cats since FoxP3 cannot be detected in viable cells.
However, it has been repeatedly shown that the suppressive feline
Treg cell population resides within the CD4
+CD25
+ phenotype
[9,10,22]. Taken together, the present study and previous reports
support the idea that feline Treg cells are defined by FoxP3, that
activated Treg cells coexpress FoxP3 and CD25, and that the
CD4
+CD25
2FoxP3
+ population represents naı ¨ve Treg cells with
proliferative potential. This remains to be confirmed in future
studies.
A question that remains is whether infection with FIV, SIV, or
HIV-1 preferentially drives Treg cell production and/or activation
during the acute phase of infection. It may be that viral proteins
directly contribute to the activation of Treg cells. Nilsson et al.
demonstrated increased FoxP3 expression and decreased apoptosis
in Treg cells cultured with HIV-1 gp120 and this is mediated
through CD4. The primary receptor used by FIV is CD134
(OX40), not CD4; however, OX40 agonists have been shown to
induce the proliferation and accumulation of Treg cells in mice
[63]. Another possible factor contributing to Treg cell induction
could be the immune response associated with pathogenic FIV,
SIV, or HIV-1 infection. Partially activated dendritic cells are
associated with HIV-1 infection and Treg cell induction [64,65].
In the Friend retrovirus model it has been shown that expansion of
the Treg cell population is dependent on the presence of CD4
+
and CD8
+ effector T cells and is independent of the level of
viremia [58,66,67]. Thus, robust T effector cell induction may
provide the cytokine milieu needed for Treg cell expansion during
FIV/SIV/HIV infections. Several studies have demonstrated
increased Treg cell:T effector cell ratios during SIV and HIV-1
Figure 9. Peripheral Treg cells are induced during acute FIV infection. (A) CD4
+CD25
hi percentages within the PBMC population were
determined by flow cytometry on days 212, 0, 7, 14, 35, and 54 post-FIV infection. Percentages were multiplied by lymphocyte absolute number to
quantify absolute numbers of CD4
+CD25
hi cells. Absolute numbers were then expressed as a percentage of day 212 values and averaged. (B)
CD4
+CD25
+FoxP3
+ percentages within the PBMC population were determined by flow cytometry, then absolute numbers were expressed as a
percentage of day 212 values and averaged. (A, B) Significance was determined relative to day 212 values. * indicates p,0.05. (C) FoxP3 mean
fluorescence intensity (MFI) within CD4
+CD25
+FoxP3
+ and CD4
+CD25
2FoxP3
+ PBMCs from vehicle control-treated cats was determined by flow
cytometry. Levels and kinetics did not significantly differ between treatment groups. (D) FoxP3 and TGF-b MFI within CD4
+CD25
+ PBMCs from vehicle
control-treated cats was determined by flow cytometry. Levels and kinetics did not significantly differ between treatment groups. (E) Percent of
CD4
+CD25
+FoxP3
+ PBMCs expressing CD62L was determined by flow cytometry. (F) Percent CD4
+Ki67
+ PBMCs from vehicle control-treated cats was
determined by flow cytometry and is compared to CD4
+CD25
+FoxP3
+ PBMC absolute number. Levels and kinetics did not significantly differ between
treatment groups. (C–F) Significance was determined relative to day 0 values. * indicates p,0.05. (G) Percent of CD4
+ T cells expressing CD25 and
FoxP3 in lymphoid tissues was determined by flow cytometry on days 14, 35, or 54 post-FIV infection. (A–G) Mean 6 SEM is shown.
doi:10.1371/journal.pone.0017183.g009
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induction correlated with Ki67 expression on lymphocytes [19],
similar to what we observed in this study (Figure 9F). Determining
the mechanism behind the Treg cell response may be important
with regard to vaccine development.
In conclusion, we report here that Treg cells present before
infection do not play a major regulatory role during acute FIV
pathogenesis. However, we found that CD4
+CD25
+FoxP3
+ Treg
cells are rapidly induced in the periphery during acute FIV
infection. Because Treg cells have been shown to be activated and
play a role in antiviral immunosuppression during chronic FIV
infection, we hypothesize that Treg cell induction during acute
FIV infection leads to the development of an activated Treg cell
population that plays a major role in suppression of antiviral
responses during chronic infection [10,18,70]. Additional studies
to determine whether Treg cell depletion prior to therapeutic
vaccination during chronic lentiviral infection can boost immunity
should be performed.
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